MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Core Insights - MeiraGTx Holdings plc has announced a strategic collaboration with Eli Lilly in ophthalmology, focusing on the AAV-AIPL1 program for treating Leber congenital amaurosis 4 (LCA4) [1][2] Collaboration Details - MeiraGTx grants Lilly worldwide exclusive rights to the AAV-AIPL1 program, which has shown unprecedented clinical results, restoring vision in 11 legally blind children [2] - Lilly will also gain access to MeiraGTx's gene therapy technologies, including novel intravitreal capsids and AI-generated promoters for retinal applications [3] - The agreement includes an upfront payment of $75 million, with potential milestone payments exceeding $400 million, along with tiered royalties on licensed products [4] Company Background - MeiraGTx is a clinical-stage genetic medicines company with a comprehensive pipeline, including four late-stage clinical programs targeting inherited and common diseases [6] - The company has developed advanced manufacturing capabilities, with five global facilities, including two licensed for GMP viral vector production [6] - MeiraGTx's riboswitch technology allows precise control of gene expression through oral small molecules, applicable to various therapeutic areas [8]